A novel clinically applicable biomarker for testing HRD status based on the mutational signatures: Results for the phase 2 trial of olaparib maintenance monotherapy in patients with primary high-grade ovarian carcinoma (2271)

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2023-09, Vol.176, p.S297-S298
Main Authors: Oda, Katsutoshi, Nishijima, Akira, Hasegawa, Kosei, Sato, Sho, Kato, Kazuyoshi, Mori, Mayuyo, Nagao, Shoji, Matsumura, Noriomi, Kagabu, Mahahiro, Takenaka, Masataka, Yoshihara, Kosuke, Konno, Yosuke, Hamanishi, Junzo, Tokunaga, Hideki, Ogasawara, Aiko, Ueda, Keiko, Kashiwabara, Kosuke, Aoki, Takashi, Nishimura, Kunihiro, Tatsuno, Kenji, Aburatani, Hiroyuki
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2023.06.389